Summary
Aflac Incorporated's 2014 Form 10-K highlights a year of resilience amidst a weakening yen, reporting total revenues of $22.7 billion and net earnings of $3.0 billion. The company's operations are heavily concentrated in Japan, which accounted for 72% of total revenues and 82% of total assets in 2014. Aflac Japan's performance was impacted by the yen's depreciation against the U.S. dollar, leading to a reported decrease in dollar-denominated revenues and net earnings compared to 2013. However, on a yen-operating basis, Aflac Japan showed stable pretax operating earnings, driven by strong performance in its core cancer and medical insurance products, with the introduction of the "New Cancer DAYS" product showing promising early results. In the U.S., Aflac U.S. demonstrated moderate growth in premium income and pretax operating earnings, supported by product enhancements and strategic sales initiatives. The company continued its share repurchase program, returning $1.2 billion to shareholders through repurchases and dividends in 2014. Aflac's strong capital position and robust risk management framework are key strengths, with the company maintaining high solvency margin ratios and regulatory capital levels in both its U.S. and Japanese operations. The report also details the company's exposure to market risks, particularly currency fluctuations and interest rate sensitivity, and outlines its hedging strategies to mitigate these risks.
Financial Highlights
34 data points| Revenue | $22.73B |
| SG&A Expenses | $2.26B |
| Operating Income | $4.25B |
| Interest Expense | $317.00M |
| Net Income | $2.95B |
| EPS (Basic) | $3.27 |
| EPS (Diluted) | $3.25 |
| Shares Outstanding (Basic) | 902.41M |
| Shares Outstanding (Diluted) | 908.00M |
Key Highlights
- 1Aflac Japan remains the dominant contributor to Aflac's overall financial performance, accounting for 72% of total revenues in 2014. The weakening yen negatively impacted dollar-denominated results, though yen-based operating earnings remained stable.
- 2The company introduced "New Cancer DAYS" in Japan, which showed a significant 176% increase in cancer insurance sales for Q4 2014, indicating positive market reception.
- 3Aflac U.S. reported a modest increase in premium income and pretax operating earnings, with strategic sales initiatives and product enhancements contributing to growth.
- 4Shareholder returns were robust, with $1.2 billion allocated to share repurchases and dividends in 2014, demonstrating a commitment to capital allocation.
- 5Aflac maintains a strong financial position, evidenced by high solvency margin ratios in Japan and robust risk-based capital ratios in the U.S., indicating strong capital adequacy.
- 6The company proactively manages market risks, particularly currency fluctuations and interest rate impacts, through hedging strategies and a diversified investment portfolio.
- 7Despite challenges like low interest rates in Japan, Aflac's diversified product portfolio and strong distribution channels in both markets provide a foundation for continued stability and growth.